Dr. Christian Trendelenburg, Novartis - Qepler Summits And Conferences

Dr. Christian Trendelenburg

Senior Toxicologist & Project Leader (PTM)
Basel, Switzerland
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Christian-Friedrich Trendelenburg is a senior toxicologist in Preclinical Safety (PCS) at the Novartis Institutes for Biomedical Research (NIBR) in Basel/Switzerland.

He is a scientific expert for the safety evaluation of impurities, extractables/leachables and excipients, with major focus on the safety evaluation of pharmaceutical products for children.

As Preclinical Safety project leader in the Neuroscience and Global Health therapeutic areas he represents PCS in global pro-ject teams to support drug development by summarizing, evaluating, and interpreting nonclinical safety aspects.

He graduated in biochemistry from the University of Kaiserslautern/Germany and has a PhD (Dr. rer. nat.) in Toxicology.

Christian has a strong background in all areas of safety sciences including agrochemical, food, chemical (home & personal care) and pharmaceutical products.

He is a EUROTOX-certified toxicologist and member of the German and Swiss toxicological societies (DGPT & SST).

Related Sessions:

Extractables & Leachables
Summit 2019

Get the latest updates in regulation, analytical testing, risk & safety assessment, biocompatibility.
  • 15 Oct 2019
  • Berlin, DE
  • Pharma
Day 1: Tuesday, 15 October 2019
CASE STUDY: Safety assessment of extractables/leachables: Challenges with different administration routes.
  • Safety thresholds for extractables/leachables in pharmaceutical products will be introduced
  • Applicability of these thresholds to products for different administration routes will be discussed
  • Specific safety considerations and approaches for parenteral and ophthalmic products are summarized
View Details

2nd Annual Extractables &
Leachables Summit 2020

Get the latest updates in regulation, analytical testing, risk & safety assessment, biocompatibility.
  • 22 Oct 2020
  • Prague, CZ
  • Pharma
Day 2: Friday, 23 October 2020
CASE STUDY: To Be Announced.
View Details